Sign In
Buy ONTTF
$1.90
+0 (+0%)
At Close: Jun 03, 2026
Leading banks back Oxford Nanopore after London Calling showcases maturing platform
07:45am, Tuesday, 26'th May 2026
Oxford Nanopore Technologies PLC (LSE:ONT), the LSE-listed DNA sequencing company, has drawn positive reviews from RBC Capital Markets and Citi following its annual London Calling customer conference
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
06:40am, Tuesday, 17'th Mar 2026
OXFORD, England & TOKYO--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations
Oxford Nanopore Technologies plc (ONTTF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
05:42pm, Wednesday, 11'th Mar 2026
Oxford Nanopore Technologies plc (ONTTF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing
04:18am, Tuesday, 10'th Mar 2026
OXFORD, England & VIENNA--(BUSINESS WIRE)-- #Nanopore--ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's f
Citi keeps 'buy' rating on Oxford Nanopore as profitability target holds despite revenue miss
09:33am, Tuesday, 03'rd Mar 2026
Oxford Nanopore Technologies PLC (LSE:ONT), the DNA sequencing company, retained its 'buy' rating at Citi after reporting second-half 2025 adjusted earnings ahead of expectations, even as it issued lo
Oxford Nanopore Technologies plc (ONTTF) Q4 2025 Earnings Call Transcript
05:37pm, Monday, 02'nd Mar 2026
Oxford Nanopore Technologies plc (ONTTF) Q4 2025 Earnings Call Transcript
Oxford Nanopore Technologies plc (ONTTF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:55pm, Monday, 12'th Jan 2026
Oxford Nanopore Technologies plc (ONTTF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Oxford Nanopore rises on strong 2025 revenue growth
05:01am, Monday, 12'th Jan 2026
Shares in Oxford Nanopore Technologies PLC (LSE:ONT) rose 8% to 152p on Monday after the DNA sequencing group said its revenue for 2025 would come in slightly ahead of guidance, helped by double-digit
Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe
01:30am, Monday, 12'th Jan 2026
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--Oxford Nanopore Technologies today announces that the GridION™ Dx is now both CE and UKCA marked, making it the company's first IVD device registered in
Oxford Nanopore Technologies plc (ONTTF) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
12:53pm, Tuesday, 02'nd Dec 2025
Oxford Nanopore Technologies plc (ONTTF) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
12:49pm, Wednesday, 15'th Oct 2025
OXFORD, England--(BUSINESS WIRE)-- #Nanopore--At the American Society of Human Genetics (ASHG) 2025 industry session on 16th October, Oxford Nanopore Technologies will share its latest developments in
Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032
07:00am, Thursday, 09'th Oct 2025
Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose
Oxford Nanopore Technologies plc (ONTTF) Q2 2025 Earnings Call Transcript
07:45am, Tuesday, 02'nd Sep 2025
Oxford Nanopore Technologies plc (OTCPK:ONTTF) Q2 2025 Earnings Call September 2, 2025 3:30 AM EDT Company Participants Gordon Sanghera - Co-Founder, CEO, Chief Officer of Technology, Innovation & Pro
Oxford Nanopore falls despite underlying loss beating expectations
03:50am, Tuesday, 02'nd Sep 2025
Oxford Nanopore Technologies PLC (LSE:ONT) shares fell 2.9% after the molecular sensing specialist reported interim results in line with its recent update and reaffirmed its full-year and medium-ter
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
02:00am, Thursday, 07'th Aug 2025
OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)-- #Lifesciences--ViruSure, a global leader in pathogen safety testing for biopharmaceuticals, and Oxford Nanopore Technologies (“Oxford Nanopore”
